Neurochirurgische Klinik, Universitätsklinikum Münster, 48149 Münster, Germany.
J Neurosurg. 2011 Mar;114(3):613-23. doi: 10.3171/2010.3.JNS097. Epub 2010 Apr 16.
Accumulating data suggest more aggressive surgery in patients with malignant glioma to improve outcome. However, extended surgery may increase morbidity. The randomized Phase III 5-aminolevulinic acid (ALA) study investigated 5-ALA-induced fluorescence as a tool for improving resections. An interim analysis demonstrated more frequent complete resections with longer progression-free survival (PFS). However, marginal differences were found regarding neurological deterioration and the frequency of additional therapies. Presently, the authors focus on the latter aspects in the final study population, and attempt to determine how safety might be affected by cytoreductive surgery.
Patients with malignant gliomas were randomized for fluorescence-guided (ALA group) or conventional white light (WL) (WL group) microsurgery. The final intent-to-treat population consisted of 176 patients in the ALA and 173 in the WL group. Primary efficacy variables were contrast-enhancing tumor on early MR imaging and 6-month PFS. Among secondary outcome measures, the National Institutes of Health Stroke Scale (NIH-SS) score and the Karnofsky Performance Scale (KPS) score were used for assessing neurological function.
More frequent complete resections and improved PFS were confirmed, with higher median residual tumor volumes in the WL group (0.5 vs 0 cm(3), p = 0.001). Patients in the ALA group had more frequent deterioration on the NIH-SS at 48 hours. Patients at risk were those with deficits unresponsive to steroids. No differences were found in the KPS score. Regarding outcome, a combined end point of risks and neurological deficits was attempted, which demonstrated results in patients in the ALA group to be superior to those in participants in the WL group. Interestingly, the cumulative incidence of repeat surgery was significantly reduced in ALA patients. When stratified by completeness of resection, patients with incomplete resections were quicker to deteriorate neurologically (p = 0.0036).
Extended resections performed using a tool such as 5-ALA-derived tumor fluorescence, carries the risk of temporary impairment of neurological function. However, risks are higher in patients with deficits unresponsive to steroids.
越来越多的研究数据表明,对恶性胶质瘤患者进行更积极的手术可以改善预后。然而,扩大手术范围可能会增加发病率。这项随机的 III 期 5-氨基酮戊酸(ALA)研究调查了 5-ALA 诱导的荧光作为提高切除率的一种手段。中期分析显示,完全切除率更高,无进展生存期(PFS)更长。然而,在神经恶化和额外治疗的频率方面,差异不大。目前,作者关注最终研究人群中的后一方面,并试图确定细胞减灭术如何影响安全性。
将恶性脑肿瘤患者随机分为荧光引导(ALA 组)或常规白光(WL 组)显微镜手术。最终意向治疗人群包括 176 例 ALA 组和 173 例 WL 组患者。主要疗效变量为早期磁共振成像增强肿瘤和 6 个月无进展生存期。次要终点包括美国国立卫生研究院卒中量表(NIH-SS)评分和卡氏功能状态量表(KPS)评分,用于评估神经功能。
证实了更频繁的完全切除和改善的 PFS,WL 组的中位残留肿瘤体积更高(0.5 与 0cm3,p = 0.001)。ALA 组患者在 48 小时时 NIH-SS 恶化更为频繁。有风险的患者是那些对类固醇无反应的缺陷患者。KPS 评分无差异。关于结局,尝试了一个将风险和神经缺陷结合起来的终点,结果显示 ALA 组患者的结果优于 WL 组患者。有趣的是,ALA 患者的重复手术累积发生率显著降低。当按切除程度分层时,不完全切除的患者神经恶化更快(p = 0.0036)。
使用 5-ALA 衍生肿瘤荧光等工具进行的扩大切除手术会导致暂时的神经功能障碍风险。然而,对类固醇无反应的缺陷患者风险更高。